Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bionacre BG (BG Granules) is a nacre-based bone graft biomaterial developed by MEGA BIOPHARMA for bone regeneration and repair. Utilizing the company's proprietary Bionacre technology, the product is derived from mother-of-pearl and features a dual composition of ceramic and organic components. The mineral phase provides an osteoconductive framework that supports bone cell attachment and growth, while the organic matrix contains bioactive compounds that facilitate osteoinduction. Bionacre BG is bioresorbable, with a resorption rate of approximately 9.8 mm³ per week, and is intended for surgical implantation or local placement in bone defects and non-load bearing voids within dental and orthopedic surgical contexts.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Bionacre BG.